Date: 2012-04-02
Type of information:
phase: 2b
Announcement: presentation of data at several international meetings
Company: Aicuris (Germany)
Product: Letermovir (AIC246)
Action
mechanism: Letermovir (AIC246) is an innovative, highly active and specific inhibitor of HCMV. It stems from a novel chemical class (quinazolines) and addresses a novel target (the viral terminase). Based on this new mode of action, it retains full activity also against viruses which are resistant to marketed drugs (invariably inhibitors of the viral polymerase).
Letermovir has received Orphan Drug Status in the US and EU and Fast Track Designation in the US.
Disease: prevention of HCMV (human cytomegalovirus) disease
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: AiCuris has announced that data on the positive outcome of Letermovir (AIC246) tested in a phase 2b trial in transplant patients will be disclosed at several international meetings on behalf of the AIC246 study team. Initially, Dr. Holger Zimmermann will present phase 2b data on Letermovir (AIC246) for the prevention of HCMV infections in patients after human blood precursor cell transplantation at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will be held in London from 31st March to 3rd April 2012.
Prof. Gerhard Ehninger will present the respective data at the EBMT (European Group for Blood and Marrow Transplantation) meeting in Geneva, Switzerland during the Session of the Infectious Disease Working Party at 03 April 2012 starting at 4pm.
Later this month on 18th April 2012 Dr. Holger Zimmermann will present an overview on Letermovir (AIC246) including clinical phase 2b data within the clinical symposium at the International Conference on Antiviral Research (ICAR) meeting in Sapporo , Japan.
